Apotex believes that every man, woman and child is entitled to affordable medical care and freedom from pain and suffering.
For close to 40 years, we have continued to meet the challenges of today and tomorrow and are solely committed to building one of the world's most successful pharmaceutical companies. With our primary objective of advancing generics and leveraging our global strategy of vertical integration, Apotex has built an impressive scientific and manufacturing infrastructure.
Manufacturing, technology and science are the core focuses of our position in the pharmaceutical industry. The world has a tremendous need for quality, affordable medicines, and Apotex wants to meet those needs for the long term.
We have built the facilities, the scientific R&D base and the technology to meet the healthcare needs of the world.
Born out of entrepreneurial efforts and strong scientific roots, Today, Apotex is the largest Canadian owned pharmaceutical company.
The Apotex Group of Companies has a simple yet powerful mission... "Apotex is an independent, dynamic, Canadian pharmaceutical company committed to R&D, manufacturing and distributing a broad range of high quality, affordable medicines to patients, healthcare providers, payers and governments worldwide. We will always meet global regulatory, quality and compliance requirements. We value and respect our employees, our business partners, our suppliers, our customers and the communities we serve while operating with accountability and integrity in everything we do."
In 1974, with only 2 employees and no sales, we had a future vision for our success and growth. Today, our vision realized, Apotex leads the fight for affordable healthcare all over the globe.
Presently, we produce over 300 medicines in over 4000 formats and dosages.
Supported by close to 2000 scientific staff including 110 PhDs, our R&D program has well over 600 products under development. Our rich products pipeline comprises solid dosage and bio-pharmaceuticals across all technology platforms. This is accomplished through global leadership and capabilities in the development of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations.
We have facilities in different countries to manufacture APIs and finished dosage forms.
The Apotex Group of Companies occupies over 3.4 million square feet of facilities with state-of-the art technology to meet the needs of the world's healthcare system. Research for Apotex also includes innovative medicines.
Apo-Pharma was created as a separate company to handle innovative medicines. Its main accomplishment to date is the approval in over 60 countries around the world of "Ferriprox" for the treatment of Thalassemia. The pipeline includes iron chelators for other indications.
The Apotex Group and our facilities are recognized around the world as among the best. This has resulted in approvals by the U.S. Food and Drug Administration, the Canadian Therapeutics Products Directorate, the European Medicines Evaluation Agency and the Australian Therapeutics Goods Administration.
These approvals have opened the doors for export to over 115 countries globally. Our international division continues to be a focus for growth as Apotex continues to strive to be a worldwide leader in generics.
Our true strength is our employees and our vision. From the top down, we are an organization dedicated to serving the needs of our customers. Our employees understand that putting the needs of our customers first is critical.
Other important components to the Apotex Group include Aveva and Accucaps. Located in Florida, Aveva's primary focus is the research, development and manufacturing of transdermal pharmaceutical products. Accucaps, is a leader in soft gel technologies in North America.
As you can see, we are committed to making healthcare affordable. During our 40 year history, we have built a tremendous presence in generic pharmaceuticals and we look forward to the next 40 years of growth, commitment to excellence and superior service to our customers.
We are proud to say, at Apotex, our innovation does not end in the lab. It just starts there... on the road to Advancing Generics.